Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc

Cancer Gene Therapy

Volumn 14, Issue 2, 2007, Pages 220-226

  Boffa, L C ^a   Cutrona, G ^a   Cilli, M ^a   Matis, S ^a,b   Damonte, G ^b   Mariani, M R ^a   Millo, E ^b   Moroni, M ^c   Roncella, S ^c   Fedeli, F ^c   Ferrarini, M ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ASL5 La Spezia ^*  (Italy)

Author keywords

Burkitt's lymphoma; c myc; E enhancer; Gene downregulation; PNA

Indexed keywords

GLYCYLCYSTEINYLALANYLGLYCYLGLYCYLALANYLALANYLGLYCYLCYSTEINYLALANYLGLYCYL GLYCYLTHREONYLCYSTEINYLALANYLCYSTEINYLCYSTEINYLGLYCINE PROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALINE; GLYCYLTHREONYLALANYLGLYCYLGLYCYLALANYLALANYLGLYCYLTHREONYLALANYLGLYCYL GLYCYLTHREONYLCYSTEINYLALANYLTHREONYLCYSTEINYLGLYCINE PROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALINE; PEPTIDE NUCLEIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; FEMALE; GENE CONTROL; GENE SEQUENCE; GENE TRANSLOCATION; HETEROZYGOSITY; INOCULATION; LATENT PERIOD; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; SCID MOUSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; BASE SEQUENCE; BURKITT LYMPHOMA; CELL DIVISION; GENES, MYC; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PEPTIDE NUCLEIC ACIDS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS;

EID: 33846248757     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701002     Document Type: Article

References (10)

1. Nielsen PE. Peptide nucleic acid targeting of double-stranded DNA. Methods Enzymol 2001; 340: 329-340.
2. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotech 2000; 18: 300-303.
3. Magor BG, Ross DA, Pilstrom L, Warr GW.Transcriptional enhancers and the evolution of the IgH locus. Immunol Today 1999; 20: 13-17.
4. Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarf S et al. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the Eμ enhancer. Cancer Res 2003; 63: 6144-6148.
5. Boffa LC, Cutrona G, Cilli M, Mariani MR, Matis S, Pastorino M et al. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's Lymphoma. Oligonucleotides 2005; 15: 85-93.
6. Roncella S, Cutrona G, Favre A, Ulivi M, Fais F, Signorini A et al. Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implication for lymphomagenesis in acquired immunodeficiency syndrome. Blood 1996; 15: 599-608.
7. Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla Favera R, Neri A et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516-1526.
8. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for burkitt's lymphoma. J Immunol 2005; 174: 3015-3023.
9. Cutrona G, Ulivi M, Fais F, Roncella S, Ferrarini M. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. J Exp Med 1995; 18: 699-711.
10. Sidman CL, Shaffer DJ, Jacobsen K, Vargas SR, Osmond DG.Cell populations during tumorigenesis in Em-myc transgenic mice. Leukemia 1993; 7: 887-895.